2. Academic Validation
  3. Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer

Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer

  • J Gynecol Oncol. 2024 Jul;35(4):e82. doi: 10.3802/jgo.2024.35.e82.
Chinmoy K Bose 1 2,  Nirban Basu 3
Affiliations

Affiliations

  • 1 Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, India.
  • 2 The Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi, India. [email protected].
  • 3 Department of Paediatric Surgery, NRS Medical College, Kolkata, India.
PMID: 38789395 DOI: 10.3802/jgo.2024.35.e82
Abstract

MEDI5752 is a monovalent bispecific immunotherapy and is strategically unique as it combines both anti programmed cell death 1 and anti cytotoxic T-lymphocyte-associated protein 4 action. This is one of the first of this kind of molecule. The development of this molecule had been very interesting which is not usually described in regular clinical oncology journals thus losing an important piece of history of an upcoming subject. Only some phase I results in such development is published so far and no full report on this is available till now. This effort will try to record the facts and chain of events which actually occurred in inventing and bringing it in phase III trial.

Keywords

Bispecific; Immunotherapy; MEDI 5752, Volrustomig; Poor Response.

Figures
Products